Correction: Real‑world safety profile of eculizumab in patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, or generalized myasthenia gravis: an integrated analysis of post‑marketing surveillance in Japan
本文未提供摘要，请点击“查看全文”查看完整内容。